Compositions and methods for inhibiting expression of CD274/PD-L1 gene

1. A double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand consists of one of the antisense sequences of SEQ ID NOs: 806, 808, 810, and 812.

2. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.

3. The dsRNA of claim 2 , wherein at least one of said modified nucleotides is chosen from the group consisting of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

4. The dsRNA of claim 2 , wherein said modified nucleotide is chosen from the group consisting of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

5. The dsRNA of a claim 1 , wherein the region of complementarity is between 19 and 21 nucleotides in length.

6. The dsRNA of claim 5 , wherein the region of complementarity is 19 nucleotides in length.

7. The dsRNA of claim 1 , wherein each strand is no more than 30 nucleotides in length.

8. The dsRNA of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

9. The dsRNA of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 2 nucleotides.

10. The dsRNA of claim 1 , further comprising a ligand.

11. The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand consisting of a sense strand sequence selected from SEQ ID NOs: 805, 807, 811, and 813.

12. A cell containing the dsRNA of claim 1 .

13. The dsRNA of claim 1 , further comprising a pharmaceutically acceptable carrier.